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The immune system response and inflammation play a key role in brain injury during and after a stroke. The acute
immune response is responsible for secondary brain tissue damage immediately after the stroke, followed by
immunosuppression due to sympathetic nervous system activation. The latter increases risk of infection complications,
such as pneumonia. The pneumonia-related inflammatory state can release a bystander autoimmune response against
central nervous system antigens, thereby initiating a vicious circle. The aim of this review is to summarize the
relationship between ischemic stroke, sympathetic nervous system activation and pulmonary infection.
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It is estimated that pulmonary and urinary tract infections
occur in up to one third of patients suffering from is-
chemic stroke within the first days after the vascular
event [1,2]; however, frequency of these infections var-
ies between studies [3]. The largest trial undertaken to
investigate the effect of pneumonia on mortality in
hospitalized patients with acute stroke reported a 27%
30-day mortality rate in 635 patients due to pneumonia
compared to 4% death rate among patients free from
severe respiratory infections (P < 0.001) [4]. The most
important predictors of post-stroke infection include
older age, stroke severity (that is National Institutes of
Health Stroke Scale of more than 16 in 0 to 42 scale,
Barthel Index of less than 5 in 0 to 20 scale, Glasgow
Coma Scale score of less than 9), larger area of the infarct,
and dysphagia [4,5].
Dysphagia is a well-recognized risk factor for post-stroke
pneumonia. Traditionally, it has been explained by ab-
normal dopamine transmission and/or a decrease of
substance P in the gastrointestinal tract resulting in
the impairment of the swallowing reflex [6]. Dysphagia is
a frequent indication for tube feeding as a prophylactic* Correspondence: pawelwinklewski@wp.pl
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unless otherwise stated.procedure against post-stroke pneumonia, however, with
very limited effects [7]. As none of the modalities used
to treat dysphagia provide efficient protection against
post-stroke pneumonia, it is warranted to discern alter-
native etiologies for the respiratory insult, including a
stroke-induced systemic immune response [3]. This as-
sumption corresponds with the observation that up to
half of the patients presenting with pneumonia do not
aspirate [8]. Furthermore, Prass et al. [9] demonstrated
that experimental stroke can promote bacterial aspir-
ation from harmless intranasal colonization, leading to
pneumonia. Prevention of infections by β-adrenergic
receptors (β-ARs) blockade suggests that immunodepres-
sion due to sympathetic nervous system (SNS) hyperactiv-
ity is essential for the development of aspiration-induced
pneumonia [10]. The insular cortex strokes associated
with excessive sympathetic stimulation increase the risk of
post-stroke pneumonia in humans [11].
Acute immune activation after the stroke is respon-
sible for secondary brain injury [12,13]. It is followed
by immunosuppression, consequently increasing the risk
of infections such as pneumonia. Recently, multiple ex-
perimental and clinical studies were performed to explain
the relationship between infection after the stroke and im-
munosuppression induced by the SNS [9,10,14].
Ischemic stroke gives rise to an intense activation of the
SNS and the release of catecholamines [9,10]. Primarytral. This is an Open Access article distributed under the terms of the Creative
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lymph nodes) lymphoid organs are abundantly innervated
by autonomic, mostly sympathetic efferent fibers. The
SNS primary neurotransmitter - norepinephrine is re-
leased into the lymphoid tissue and modulates the
function of immune cells [15]. The stroke-induced SNS
activation is responsible for lymphopenia, impaired func-
tion of monocytes, shift from Th1 to Th2 cytokine pro-
duction and increased lymphocyte apoptosis, observed in
the affected patients [9-11]. Pharmacological inhibition of
the peripheral SNS activation with a beta-blocker was
shown to prevent immunosuppression in experimental
stroke [10]. A retrospective analysis showed that the use
of beta-blockers is associated with reduced risk of early
death in patients with ischemic stroke [16]. The aim of
this review is to discuss the relationship between ischemic
stroke, SNS activation and pulmonary infection.
Immune system in stroke
Ischemic cerebral stroke results from a transient or
permanent reduction in local blood flow. Focal cerebral
ischemia initiates a complex process including the release
of neurotransmitters and activation of the immune sys-
tem. Recently, the inflammatory mechanisms involved in
the pathogenesis of brain injury and brain repair mecha-
nisms (that is neural plasticity) have received considerable
attention [12,13].
The response of the immune system to stroke is
biphasic, with early transient activation lasting up to
24 hours [17,18] followed by systemic immunodepression,
called brain-induced immunosuppression [14,18]. The
suppression of cell-mediated immunity (lymphopenia,
monocyte deactivation, shift from Th1 to Th2 cytokine
production) 72 hours after experimental stroke is often
associated with spontaneous bacteremia and pneumo-
nia [10]. Prass et al. [10] demonstrated that reduced
IFN-γ production as well as impaired natural killer
(NK) and T cell response are the critical stroke-related
failures in antibacterial defense. Other animal studies
demonstrated decrease in IL-10 release by endotoxin-
stimulated whole blood cells after infusion of IL-1β
into the brain. This effect was attributed to activation
of the hypothalamic-pituitary-adrenal (HPA) axis and
the sympatho-adrenal medullary axis [19].
Spleen
Offner et al. [17] observed that 6 and 22 hours after ex-
perimental stroke in mice, activated spleen cells secreted
significantly higher amounts of TNF-α, IFN-γ, IL-6,
monocyte chemotactic protein 1 (MCP-1), and IL-2
than splenocytes in control mice. Moreover, stimulated
splenocytes from stroke-injured animals strongly expressed
chemokines and chemokine receptors (CCR), including
macrophage inflammatory protein 2 (MIP-2) and CCR2,CCR7 and CCR8 6 hours after stimulation; MIP-2, IFN-
γ-induced protein 10 (IP-10), CCR1, and CCR2 were
expressed 22 hours after stimulation. Experimental stroke
increased the release of inflammatory cytokines from
activated T cells [17]. Twenty-four hours later, a higher
CD4/CD8 T cell ratio and enhanced production of
TNF-α and IFN-γ by blood and spleen lymphocytes
were reported [18].
These observations correspond with the finding of
Hardy et al. that phenylephrine (an α1−AR agonist) in-
duces contractions of the spleen in a dose-dependent
manner [20]. Therefore, the spleen may serve as a dy-
namic reservoir of leukocytes, which are mobilized by
catecholamines and migrate to the injured brain. Inter-
estingly, the reduction in spleen size could be inhibited
by α1-AR antagonist prazosin. However, this effect did
not influence the infarct size, demonstrating that these
two events are not directly linked to each other [21].
Offner et al. [22] suggested that spleen shrinkage was
due to profound apoptosis of the lymphocyte popula-
tion. However, it seems unlikely that even an extensive
apoptosis would eliminate lymphocytes massively to
reduce the spleen size by 40%, yet preserve their relative
count in the organ [22]. Moreover, according to another
report, the spleen may release large numbers of platelets
upon low-dose epinephrine infusion [23]. The platelets
may, as described below, significantly contribute to the
development of an acute inflammatory response in the
brain.
Liver
Wong et al. [24] reported that noradrenergic innerv-
ation of the liver modulates the function of intrahepatic
invariant NK T cells accounting for systemic immune
suppression after experimental ischemic stroke. Invari-
ant NK T cells are a unique subset of lymphocytes that
express a repertoire of highly restricted T cell receptors.
These receptors recognize microbe-specific or endogen-
ous glycolipids presented by the major histocompatibil-
ity complex class I-like molecule CD1d. They are
believed to play a critical role in host defense to various
microbial pathogens as they are capable for a rapid re-
lease of cytokines (such as INF- γ) and chemokines.
These mediators contribute considerably to the recruit-
ment and activation of various leukocyte subsets, in-
cluding neutrophils and macrophages. Invariant NK T
cells reside in the vasculature, mainly in the liver and
spleen [25]. Either blockade of β-ARs with propranolol
or depletion of noradrenergic nerve terminals in the
liver boost the immune response by increasing IFN-γ se-
cretion from invariant NK T cells. Conversely, injection of
noradrenaline into the liver downregulates inflammatory
mechanisms by attenuating the functions of invariant NK
T cells [24].
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Cerebral ischemia induces the expression of TNF-α,
IL-1β, IL-6, inducible nitric oxide synthase (iNOS) and
TNF-α receptors in the endothelium of cerebral arteries
[26,27]. Furthermore, TNF-α, IL-1β, epidermal growth
factor (EGF), and basic fibroblast growth factor (bFGF)
can modify the expression and function of endothelin
receptors in cultured rat middle cerebral arteries [28].
Upregulation of the endothelin receptor in experimental
stroke may be due to the effect of cytokines and growth
factors [27]. This mechanism may facilitate cerebral
vessel contraction in vivo, and consequently worsen cere-
brovascular risk by lowering cerebrovascular reserves
and increase the vulnerability of the brain to cerebral
ischemia [29].
Despite intensive studies, the physiological role of the
SNS in the regulation of cerebral blood flow remains far
from clear [30-32]. Studies demonstrating SNS involve-
ment in the regulation of cerebral blood flow [33,34], in-
dicate that the stroke-induced SNS activity fluctuations
are a significant factor of impaired cerebral autoregulation
[35,36]. In particular, massive release of catecholamines
may further amplify the effects of upregulated endothelin
receptor. Thus, the pro-inflammatory signals and SNS
activation promote microvascular occlusion and may
increase the infarct size [37]. Regulation of cerebral
blood flow might also be impaired by the administra-
tion of tissue plasminogen activator used to improve
the perfusion of ischemic areas [38].
Early restoration of blood flow remains the treatment
of choice for limiting brain injury following ischemic
stroke. While reperfusion of the ischemic brain is desir-
able, tissue damage may result from reperfusion per se.
The accumulation of T cells in post-capillary venules is
accompanied by the recruitment of adherent platelets
[39]. As mentioned above, large numbers of platelets are
released from the spleen following sympathetic stimula-
tion [23]. A novel concept of ‘thrombo-inflammation’ sug-
gests that there is a strong correlation between thrombus
formation and inflammation, and early platelet adhesion/
activation may exacerbate infarct development following
cerebral ischemia and reperfusion [40,41].
Blood–brain barrier breakdown
A schematic time-course of the microglial cells, neutrophils
and T lymphocytes after stroke was shown in Figure 1.
Microglial cells, the resident macrophages of the brain,
are activated within minutes of the onset of ischemia.
They produce a plethora of pro-inflammatory mediators,
including reactive oxygen species (ROS), IL-1β, IL-6, and
TNF-α [42,43], which further exacerbate tissue damage
[44]. Microglial cell activation plays a crucial role in the
increase of blood–brain barrier permeability and the early
infiltration of circulating leukocytes into the brain [45,46].The post-ischemic peak of microglial proliferation is ob-
served at 48 to 72 hours after focal cerebral ischemia and
may last for several weeks after the initial injury [47,48].
In contrast to rapid response of resident microglia,
blood-derived leukocytes are recruited to the brain tissue
usually with a delay of hours to a few days. Neutrophils
are among the first leukocytes to infiltrate the ischemic
brain (30 minutes to a few hours of focal cerebral ische-
mia), peak (24 to 72 hours), and then decrease rapidly
[49,50]. On the other hand, Gelderblom et al. [51] ques-
tioned this scenario, suggesting that the infiltration of
other inflammatory cells, including macrophages, lympho-
cytes, and dendritic cells may precede neutrophil influx.
Activation of spleen neutrophils under physiological con-
ditions is modulated by the SNS [52]. Spleen contraction
induced by the SNS activation and blood–brain barrier
breakdown after ischemic stroke may facilitate their mi-
gration to the injured brain. Nevertheless, the clear role of
neutrophils in the pathogenesis of ischemic stroke is far
from being elucidated.
T lymphocytes are central to the development of a
sustained inflammatory response and accumulate in the
ischemic brain within a few hours of reperfusion [53,54].
T cells may contribute to brain injury through several
potential mechanisms. Cytokines and chemokines released
by T helper (TH) and T cytotoxic (TC) cells (which are
IL-12, IL-17, and IL-23) may exacerbate post-stroke in-
flammation and increase infarct area [55,56]. Further-
more, cytokines and chemokines are likely to increase
the expression of vascular adhesion molecules and attract
other immune cells into the brain resulting in widespread
apoptosis [57]. CD3+ cells are a major source of INF-γ
and perforin in the ischemic hemisphere [58] whereas TC
cells directly induce cell necrosis and apoptosis by the re-
lease of cytotoxins or activation of the Fas receptor [59].
Finally, T lymphocytes may release large amounts of ROS
[53]. Thus, it is commonly accepted that T cells are a
major source of pro-inflammatory cytokines in the brain
after the stroke [60].
In patients with the ischemic event, the number of T, B
and NK lymphocytes in the circulation is quickly reduced
[10,61], possibly as an endogenous protective mechanism
attenuating local inflammatory process in the brain [61].
A profound systemic immunodepression occurs as soon
as 12 hours after the stroke and persists for several weeks
[10,62]. This immunodepression is due to SNS and HPA
axis hyperactivity [10] and is mediated by β2 adrenergic
receptors [63]. According to a recent emerging concept,
the immunodepression after stroke is attributable to the
increase in the number of systemic CD4+CD25+FoxP3+
regulatory T (Treg) cells [18,22]. Increased percentage of
Treg cells in bone marrow and their mobilization to the
circulation is facilitated by the stroke-induced activation
of the SNS via β2- and β3-ARs signaling, respectively [64].
Figure 1 A schematic time-course of the microglial cells, neutrophils and T lymphocytes after ischemic stroke. Percent increase in cell
count after experimental stroke in ischemic hemisphere has been estimated from the scientific literature by the authors [10,47-50,61].
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stroke, and can also follow another brain injury including
traumatic events or brain surgery [14]. Treg-mediated im-
munosuppression and increased susceptibility to subse-
quent bacterial infections can be attributed to the deficit
of IFN-γ resulting in insufficient activation of phagocytic
cells at the site of infection [64].
Brain-lung cross-talk
Neurologic conditions that cause abrupt, rapid and ex-
treme elevation in intracranial pressure give rise to an
intense activation of the SNS and the release of cate-
cholamines [65]. The non-neurological consequences
of brain injury show similarities regardless of the brain
insult and, in particular, include neurogenic pulmonary
edema (NPE) [66].
Acute lung injury (ALI) as a consequence of acute brain
injury
ALI is a diffuse heterogeneous lung injury characterized
by hypoxemia, non-cardiogenic pulmonary edema, low
lung compliance and widespread capillary leakage [67].
It has been demonstrated that approximately one third
of patients with acute brain injury develop ALI. Patients
with concomitant ALI seem to have a worse prognosis
[68,69]. The pathogenesis of ALI includes NPE, the activa-
tion of neutrophils, inflammatory mediator release, alveo-
lar/capillary barrier damage, activation of the coagulation
system, surfactant depletion and infections [64]. Brain in-
jury might also increase lung vulnerability to subsequent
deleterious mechanical or ischemia-reperfusion injury,
thereby increasing the risk of subsequent respiratory
failure [70].
NPE is a well-recognized complication of central ner-
vous system (CNS) injury [66]. The proposed mechanisms
governing NPE include a massive sympathetic discharge
following severe brain injury causing alveolar/capillary
barrier damage, intra-alveolar accumulation of protein-
rich edema fluid, hemorrhage, and atelectasis. The preciseorigin of sympathetic outflow has not yet been identified.
Nevertheless, it is believed that the ‘NPE trigger zones’ in-
clude the hypothalamus and the medulla, specifically areas
A1 and A5, the nuclei of the solitary tract, and the area
postrema [71]. It has been hypothesized that a massive
SNS discharge following CNS injury directly affects the
pulmonary vascular bed via α- and β-ARs, leading to
isolated pulmonary venoconstriction and/or endothelial
damage. This theory, termed ‘pulmonary venule adrenergic
hypersensitivity’, can explain the direct impact of nervous
system on the pulmonary endothelium, not interme-
diated by hemodynamic changes [66]. Nevertheless, the
most established is the ‘blast theory’, which combines
hemodynamic and high permeability mechanisms [72].
According to Rassler et al. the severity of pulmonary
edema evoked by experimental intravenous injection of
catecholamines correlates with pulmonary venous hyper-
tension [73]. Moreover, Theodore and Robin (1975) proved
that an increase in the pulmonary capillary wedge pres-
sure augmented fluid filtration into the pulmonary in-
terstitium [72].
There is mounting evidence that a systemic inflam-
matory response may also play a pivotal role in the de-
velopment of pulmonary dysfunction after traumatic
brain injury [74,75] or subarachnoid hemorrhage [76].
It seems that the initial sympathetic stimulation origin-
ating from the SNS may trigger a cascade of events in
the lungs, including endothelial cell dysfunction and a
systemic inflammatory response with pulmonary infiltra-
tion of neutrophils and cytokine release [75]. Cerebral
hemorrhage increases the expression of intracellular ad-
hesion molecules in both brain and lungs, resulting in
progressive neutrophil recruitment to the lung intersti-
tium and alveolar spaces with the disruption of alveolar
structures [77]. It has been proposed that sympathetic
activation of the lungs may provoke local release of cyto-
kines and chemokines [76]. Furthermore, in experimental
settings, catecholamines seem to activate NFκB in macro-
phages with subsequent inflammatory cytokine production
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manner. Upregulation of the phagocyte response via
α2-ARs enhances the acute inflammatory response [78].
In rats, NPE induced by lethal injury of the brain is
characterized by increase of pro-inflammatory cytokines,
in particular IL-6, and accumulation of immune cells
in bronchoalveolar lavage fluid [79,80]. The histo-
logical assessment of lung tissue in this model reveals
infiltration of inflammatory cells like neutrophils within
interstitial spaces [80]. Experimental studies showed
that norepinephrine infusion enhances expression of
pro-inflammatory cytokines such as IL-6, IL-1α and
IL-1β in lung tissue and in bronchoalveolar lavage fluid
[73]. The systemic increase in catecholamines augments
the release of IL-6 from lung macrophages via β2-ARs,
which in turn contributes to the development of a hyper-
coagulable state [81]. Avlonitis et al. [79] demonstrated
that administration of α-adrenergic antagonists prevented
the development of inflammatory lung injury by reducing
systemic inflammation and preserving capillary-alveolar
membrane integrity. Thus, the experimental data strongly
supports the hypothesis that the systemic increase of cate-
cholamines due to the SNS activation contributes to local
inflammation in lungs and impairs capillary-alveolar
membrane integrity via α- and β-ARs located on phago-
cytes and in the pulmonary vascular bed.
Stroke and lung injury
Mascia proposed a ‘double hit model’ to explain the
pathogenesis of lung failure associated with acute brain
injury [75]. The model was originally developed for
traumatic brain injury; however, it shares several typical
features with stroke-induced respiratory distress syndrome.
Although, stroke pathophysiology significantly differsFigure 2 Vicious circle of brain-lung inflammation during ischemic strfrom traumatic injury brain insult it is a starting point
for the local inflammation. It was shown that severe is-
chemic stroke was associated with an increase in the
total lung water content, which might have been of
neurogenic origin [82]. Nevertheless, even if the fully
developed NPE does not emerge after ischemic stroke,
an increase in the permeability of the alveolar/capillary
barrier and local inflammatory state may favor subse-
quent infections.
Modulation of bulbar reflexes, drowsiness, bed rest
and decreased ventilation rate combined with deep
immunosuppression after stroke may trigger the de-
velopment of pneumonia. Clinical data indicate that
Streptococcus pneumoniae, the most common cause of
bacterial community-acquired pneumonia [83] is also
a predominant agent responsible for respiratory infec-
tions, prolonged hospitalization, and lethality in stroke
patients [3]. By employing animal studies it was shown
that nasal inoculation of as little as 200 colony-forming
units of Streptococcus pneumonia causes severe pneumo-
nia and bacteremia after experimental stroke, whereas at
least 200,000 colony-forming units are needed to induce
pneumonia in controls [9]. Other common pathogens
such as Chlamydophila pneumoniae and Haemophilus
influenzae also contribute to the development of severe
infectious complications [83].
Post-stroke autoimmune responses
The teleological explanation for post-stroke immunosup-
pression is that it prevents the CNS from developing adap-
tive immune responses directed against self-components.
After stroke, due to brain–blood barrier breakdown,
lymphocytes infiltrate the ischemic brain allowing for
contact with CNS antigens from various CNS cell typesoke.
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more, the increase of antigens expression such as mye-
lin basic protein (MBP), neuron specific enolase, S-100
or glial fibrillary acidic protein (GFAP) are observed.
These components become ‘visible’ to the peripheral
immune system, and indeed antigen presentation within
days of stroke onset has been reported in cervical lymph
nodes [84].
In experimental studies of severe stroke, not associated
with infection, Th1 responses to MBP are uncommon.
Nevertheless, the tendency to develop a Th1 response to
MBP could be increased by lipopolysaccharide (LPS)-
mediated induction of a systemic inflammatory response
at the onset of the stroke [85,86]. In humans, a pulmonary
infection during the first 15 days after stroke increases the
likelihood of developing Th1 response to MBP and GFAP
[87]. A more robust immune response to MBP (and to a
lesser extent to GFAP) is associated with a poor outcome
at this time point [88]. Such interdependence is further
supported by the findings from the Planas et al. study
indicating that increased reactivity to brain-derived com-
pounds in cervical lymph nodes and palatine tonsil is cor-
related with worse outcome at follow-up [84]. Pulmonary
infections predominantly caused by Gram-positive organ-
isms are associated with the Th1 response, corresponding
to a fatal course of the stroke. In contrast, urinary tract in-
fections caused primarily by Gram-negative pathogens
usually do not induce Th1 response and are associated
with a better prognosis [86]. It is therefore possible that
pulmonary infection, despite immunosuppression, pro-
vokes an inflammatory response strong enough to up-
regulate the bystander adaptive autoimmune response
to brain antigens in either peripheral lymphoid organs or
in the brain itself [87]. However, it cannot be excluded
that the better prognostic consequences of urinary infec-
tions may also be related to their lower severity and mor-
tality and not only to differences in their potential role of
favoring autoimmunity after stroke.
Conclusions
Current evidence suggests that immune-sympathetic
interplay is a key point in understanding the dynamic
environment of ischemic stroke. The lungs are both
strongly affected and may actively participate in this
interplay. We propose a model that links the ‘double hit’
and ‘Th1 response to pneumonia’ theories (Figure 2).
The initial sympathetic storm directly affects the lungs
(first hit), and indirectly makes them more susceptible
to infection due to immunosuppression (second hit).
Immunosuppresion shifts the immune response from
Th1 to Th2 to protect the brain from the adaptive im-
mune response, but pneumonia may overcome this shift,
and restart Th1 bystander autoimmune response directed
against CNS antigens.In this review, we summarized the current knowledge
related to the immune-sympathetic interactions with par-
ticular emphasis on the brain-lung cross-talk during this
interplay. Better understanding of the pathomechanisms
underlying stroke is even more urgent and important
when we consider that most of the proposed experimental
therapies failed to provide benefits in clinical trials in
humans. In future research, data acquisition taking into
account the complexity of the nervous and immune sys-
tem interactions as a multisystem network most likely
represents the most promising approach in describing the
interrelations and pathways involved in stroke.
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